The HRT Gender Gap: Why Men Get Testosterone Easily and Women Fight for Estrogen

A man walks into a clinic in his late 40s. He's tired, gaining weight, losing muscle, and his libido has tanked. The doctor nods, orders a testosterone test, and writes a prescription the same week. Testosterone replacement therapy - covered by insurance, no fuss, no fight.

A woman walks into a clinic at the same age with the same symptoms - fatigue, weight gain, muscle loss, low libido - plus hot flashes, brain fog, insomnia, and anxiety. She's told it's "just aging." She's offered antidepressants. If she pushes for hormone testing, she's told her levels are "normal." If she asks about HRT, she's warned about cancer risks based on a study from 2002 that's been largely debunked.

This is the HRT gender gap. And it's not anecdotal - it's systemic.

The numbers tell the story

Here's the disparity in black and white:

• Men's testosterone replacement: 5.3 million US men use prescribed testosterone therapy. The market is worth $2.4 billion and growing. Insurance routinely covers it. TRT clinics are everywhere. The conversation is normalized.
• Women's hormone replacement: Published estimates put current HRT use among U.S. women at roughly 1.8 to 5 percent, depending on the study and the age group. Those utilization figures do not establish how many women are eligible for treatment or why they do not use it.

Men get testosterone for low energy and low libido. Women get told to exercise more and consider therapy. The double standard is breathtaking.

How did this happen?

The WHI study poisoned the well - but only for women. The 2002 Women's Health Initiative scare decimated HRT prescribing, medical education, and research funding for women's hormone therapy. There was no equivalent panic around men's testosterone therapy, despite testosterone having its own risk profile (cardiovascular events, polycythemia, liver effects).

Medical training reflects the bias. Fewer than 1 in 3 OB/GYN residency programs include a menopause curriculum. Meanwhile, men's health and testosterone therapy are standard topics in urology and endocrinology training.

The pharmaceutical industry followed the money. After the WHI, pharma companies pulled back from women's hormone research and marketing. At the same time, men's testosterone therapy became a massive growth market with heavy DTC advertising ("Is it Low T?").

Cultural dismissal of women's symptoms. There is a long, documented history of women's health complaints being attributed to psychological causes - hysteria, anxiety, depression, stress. Menopause symptoms fit this pattern perfectly: "You're not sick, you're just stressed/aging/emotional."

What the evidence actually shows

The irony is that the evidence base for women's HRT is actually stronger than for men's testosterone therapy:

• Women's HRT was studied in the Women's Health Initiative hormone trials, which randomized more than 27,000 women
• Twenty years of follow-up data exist
• Multiple international medical societies have issued consensus guidelines supporting HRT for appropriate candidates
• Since February 2026 the FDA has been approving updated labels product by product that drop the cardiovascular disease, breast cancer and probable dementia statements from the boxed warning; the endometrial cancer warning and the contraindications remain

Men's testosterone therapy, by comparison, has never been studied in a trial of comparable scale. The long-term cardiovascular effects are still debated. Yet it's prescribed freely, covered by insurance, and marketed aggressively.

The testosterone double standard

Perhaps the most absurd manifestation of the gender gap is testosterone itself. Testosterone is an important hormone for both men and women. Women produce it naturally, and it is one of the influences on sexual desire.

For men: multiple FDA-approved testosterone products, insurance coverage, widespread prescribing.

For women: zero FDA-approved testosterone products. Short-term studies of physiological doses are reassuring, but long-term safety data are limited, and no testosterone product for women has been approved. Women who are prescribed testosterone are usually given a small dose of an approved men's product, which the Global Consensus prefers, with a compounded preparation reserved for when that is not suitable; neither is typically covered by insurance.

A 2019 global consensus statement endorsed testosterone therapy for postmenopausal women with low sexual desire that causes distress, after assessment. That was seven years ago. There is still no FDA-approved product.

What's changing

The good news: the gap is narrowing, driven by:

• Cultural advocacy: Celebrities, authors, and advocates are destigmatizing menopause and demanding better care
• The FDA's labeling changes: The FDA requested product-specific boxed-warning changes in November 2025, but that regulatory action does not determine whether HRT is appropriate for an individual.
• Telehealth: Companies like Midi, Alloy, Evernow, and Winona are making HRT accessible regardless of local provider availability
• HRT prescriptions are surging: Up 72% since 2021 (per Epic Research), suggesting women are pushing past the barriers
• Workplace policies: Following the UK's lead, US companies are beginning to address menopause as a workplace issue

The bad news: structural change - medical education reform, FDA-approved testosterone for women, universal insurance coverage - will take years. In the meantime, individual women still have to advocate for themselves in a system that wasn't designed to help them.

How to close the gap for yourself

You shouldn't have to fight for the same quality of hormone care that men receive without question. But until the system catches up, here's how to advocate effectively:

1. Find a specialist. Don't try to convince a reluctant generalist. Find a provider who already understands menopause and HRT.
2. Know the evidence. If a doctor cites the WHI, you can point out that since February 2026 the FDA has approved product-specific label updates that remove the cardiovascular disease, breast cancer and probable dementia statements from the boxed warning. Updated systemic estrogen-alone labels retain the endometrial cancer warning, contraindications did not change, and other products may still carry the older warning.
3. Ask about testosterone if low desire is the problem. Testosterone is evidence-based for postmenopausal women with distressing low sexual desire (hypoactive sexual desire disorder) after a full assessment; it is not established for energy or mental clarity. If your provider says no, ask why - and consider a second opinion.
4. Don't accept "just aging" as a diagnosis. Men don't accept it. Neither should you.